Document is current
Any future updates will be listed below
-
Authors
Nag, Arundhati https://orcid.org/0000-0002-1328-1695
Mafi, Amirhossein https://orcid.org/0000-0002-8366-6785
Das, Samir
Yu, Mary Beth
Alvarez-Villalonga, Belen
Kim, Soo-Kyung https://orcid.org/0000-0002-4498-5441
Su, Yapeng https://orcid.org/0000-0002-6305-8467
Goddard, William A. III
Heath, James R. https://orcid.org/0000-0001-5356-4385
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1U54 CA199090-01)
WA State Andy Hill CARE Foundation
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R35HL150807)
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 26 April 2023
First Online: 18 May 2023
Competing interests
: J.R.H. is a consultant to Regeneron, which is a company seeking to commercialize PCC technology. All other authors declare no competing interests.
